Platelet-activating factor receptor mediates oxidized low density lipoprotein-induced migration of bone marrow-derived mesenchymal stem cells

Cellular Physiology and Biochemistry

Volumn 26, Issue 4-5, 2010, Pages 689-698

  Shin, Sang Hun ^a,b   Song, Hae Young ^a,b   Kim, Min Young ^a,b   Do, Eun Kyung ^a,b   Kim, Koan Hoi ^b   Kim, Jae Ho ^a,b  

^a Medical Research Center for Ischemic Tissue Regeneration   (Mongolia)

^b Pusan National University School of Medicine   (South Korea)

Author keywords

Chemotaxis; Mesenchymal stem cells; Migration; Oxidized low density lipoprotein; Platelet activating factor

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; GINKGOLIDE B; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38; OXIDIZED LOW DENSITY LIPOPROTEIN; PLATELET DERIVED GROWTH FACTOR BB; SMALL INTERFERING RNA; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR;

ADENOVIRUS; ARTICLE; ATHEROGENESIS; CELL MIGRATION; CELL STIMULATION; CHEMOTAXIS; CONTROLLED STUDY; ENZYME ACTIVATION; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MESENCHYMAL STEM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 78149458109     PISSN: 10158987     EISSN: None     Source Type: Journal    
DOI: 10.1159/000322336     Document Type: Article

References (47)

1. Ross R: Atherosclerosis-an inflammatory disease. N Engl J Med 1999;340:115-126.
2. Steinberg D: Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 2002;8:1211-1217.
3. Steinberg D, Parthasarathy S, Carew TE, Khoo JC, Witztum JL: Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 1989;320:915-924.
4. Galle J, Hansen-Hagge T, Wanner C, Seibold S: Impact of oxidized low density lipoprotein on vascular cells. Atherosclerosis 2006;185:219-226.
5. Ishigaki Y, Oka Y, Katagiri H: Circulating oxidized LDL: a biomarker and a pathogenic factor. Curr Opin Lipidol 2009;20:363-369.
6. Heery JM, Kozak M, Stafforini DM, Jones DA, Zimmerman GA, McIntyre TM, Prescott SM: Oxidatively modified LDL contains phospholipids with platelet-activating factor-like activity and stimulates the growth of smooth muscle cells. J Clin Invest 1995;96:2322-2330.
7. Marathe GK, Zimmerman GA, Prescott SM, McIntyre TM: Activation of vascular cells by PAF-like lipids in oxidized LDL. Vascul Pharmacol 2002;38:193-200.
8. Stafforini DM, McIntyre TM, Zimmerman GA, Prescott SM: Platelet-activating factor, a pleiotrophic mediator of physiological and pathological processes. Crit Rev Clin Lab Sci 2003;40:643-672.
9. Montrucchio G, Alloatti G, Camussi G: Role of platelet-activating factor in cardiovascular pathophysiology. Physiol Rev 2000;80:1669-1699.
10. Bussolati B, Biancone L, Cassoni P, Russo S, Rola-Pleszczynski M, Montrucchio G, Camussi G: PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 2000;157:1713-1725.
11. Axelrad TW, Deo DD, Ottino P, Van Kirk J, Bazan NG, Bazan HE, Hunt JD: Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration. FASEB J 2004;18:568-570.
12. Stengel D, O'Neil C, Brocheriou I, Karabina SA, Durand H, Caplice NM, Pickering JG, Ninio E: PAF-receptor is preferentially expressed in a distinct synthetic phenotype of smooth muscle cells cloned from human internal thoracic artery: functional implications in cell migration. Biochem Biophys Res Commun 2006;346:693-699.
13. Honda Z, Ishii S, Shimizu T: Platelet-activating factor receptor. J Biochem 2002;131:773-779.
14. Chamberlain G, Fox J, Ashton B, Middleton J: Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 2007;25:2739-2749.
15. Phinney DG, Prockop DJ: Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair-current views. Stem Cells 2007;25:2896-2902.
16. Caplan AI, Dennis JE: Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006;98:1076-1084.
17. Jeon ES, Park WS, Lee MJ, Kim YM, Han J, Kim JH: A Rho kinase/myocardin-related transcription factor-A-dependent mechanism underlies the sphingosylphosphorylcholine-induced differentiation of mesenchymal stem cells into contractile smooth muscle cells. Circ Res 2008;103:635-642.
18. Kinner B, Zaleskas JM, Spector M: Regulation of smooth muscle actin expression and contraction in adult human mesenchymal stem cells. Exp Cell Res 2002;278:72-83.
19. Wang D, Park JS, Chu JS, Krakowski A, Luo K, Chen DJ, Li S: Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor beta1 stimulation. J Biol Chem 2004;279:43725-43734.
20. Farrington-Rock C, Crofts NJ, Doherty MJ, Ashton BA, Griffin-Jones C, Canfield AE: Chondrogenic and adipogenic potential of microvascular pericytes. Circulation 2004;110:2226-2232.
21. Hirschi KK, Goodell MA: Hematopoietic, vascular and cardiac fates of bone marrow-derived stem cells. Gene Ther 2002;9:648-652.
22. Qian H, Yang Y, Li J, Huang J, Dou K, Yang G: The role of vascular stem cells in atherogenesis and post-angioplasty restenosis. Ageing Res Rev 2007;6:109-127.
23. Lee MJ, Song HY, Kim MR, Sung SM, Jung JS, Kim JH: Oncostatin M stimulates expression of stromal-derived factor-1 in human mesenchymal stem cells. Int J Biochem Cell Biol 2007;39:650-659.
24. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D: Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci \USA 1984;81:3883-3887.
25. Law RE, Meehan WP, Xi XP, Graf K, Wuthrich DA, Coats W, Faxon D, Hsueh WA: Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 1996;98:1897-1905.
26. Huang S, Jiang Y, Li Z, Nishida E, Mathias P, Lin S, Ulevitch RJ, Nemerow GR, Han J: Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 1997;6:739-749.
27. Marathe GK, Prescott SM, Zimmerman GA, McIntyre TM: Oxidized LDL contains inflammatory PAF-like phospholipids. Trends Cardiovasc Med 2001;11:139-142.
28. Beaudeux JL, Said T, Ninio E, Ganne F, Soria J, Delattre J, Soria C, Legrand A, Peynet J: Activation of PAF receptor by oxidised LDL in human monocytes stimulates chemokine releases but not urokinase-type plasminogen activator expression. Clin Chim Acta 2004;344:163-171.
29. Watson AD, Leitinger N, Navab M, Faull KF, Horkko S, Witztum JL, Palinski W, Schwenke D, Salomon RG, Sha W, Subbanagounder G, Fogelman AM, Berliner JA: Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in vivo. J Biol Chem 1997;272:13597-13607.
30. Pegorier S, Stengel D, Durand H, Croset M, Ninio E: Oxidized phospholipid: POVPC binds to platelet-activating-factor receptor on human macrophages. Implications in atherosclerosis. Atherosclerosis 2006;188:433-443.
31. Coffer PJ, Geijsen N, M'rabet L, Schweizer RC, Maikoe T, Raaijmakers JA, Lammers JW, Koenderman L: Comparison of the roles of mitogen-activated protein kinase kinase and phosphatidylinositol 3-kinase signal transduction in neutrophil effector function. Biochem J 1998;329:121-130.
32. DeCoster MA, Mukherjee PK, Davis RJ, Bazan NG: Platelet-activating factor is a downstream messenger of kainate-induced activation of mitogen-activated protein kinases in primary hippocampal neurons. J Neurosci Res 1998;53:297-303.
33. Maruoka S, Hashimoto S, Gon Y, Takeshita I, Horie T: PAF-induced RANTES production by human airway smooth muscle cells requires both p38 MAP kinase and Erk. Am J Respir Crit Care Med 2000;161:922-929.
34. Huang C, Jacobson K, Schaller MD: MAP kinases and cell migration. J Cell Sci 2004;117:4619-4628.
35. Klemke RL, Cai S, Giannini AL, Gallagher PJ, de Lanerolle P, Cheresh DA: Regulation of cell motility by mitogen-activated protein kinase. J Cell Biol 1997;137:481-492.
36. Hedges JC, Dechert MA, Yamboliev IA, Martin JL, Hickey E, Weber LA, Gerthoffer WT: A role for p38(MAPK)/ HSP27 pathway in smooth muscle cell migration. J Biol Chem 1999;274:24211-24219.
37. Matsumoto T, Yokote K, Tamura K, Takemoto M, Ueno H, Saito Y, Mori S: Platelet-derived growth factor activates p38 mitogen-activated protein kinase through a Ras-dependent pathway that is important for actin reorganization and cell migration. J Biol Chem 1999;274:13954-13960.
38. Spaeth E, Klopp A, Dembinski J, Andreeff M, Marini F: Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells. Gene Ther 2008;15:730-738.
39. Dwyer RM, Potter-Beirne SM, Harrington KA, Lowery AJ, Hennessy E, Murphy JM, Barry FP, O'Brien T, Kerin MJ: Monocyte chemotactic protein-1 secreted by primary breast tumors stimulates migration of mesenchymal stem cells. Clin Cancer Res 2007;13:5020-5027.
40. Ji JF, He BP, Dheen ST, Tay SS: Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury. Stem Cells 2004;22:415-427.
41. Kang YJ, Jeon ES, Song H Y, Woo JS, Jung JS, Kim YK, Kim JH: Role of c-Jun N-terminal kinase in the PDGF-induced proliferation and migration of human adipose tissue-derived mesenchymal stem cells. J Cell Biochem 2005;95:1135-45.
42. Lee MJ, Jeon ES, Lee JS, Cho M, Suh DS, Chang CL, Kim JH: Lysophosphatidic acid in malignant ascites stimulates migration of human mesenchymal stem cells. J Cell Biochem 2008;104:499-510.
43. Li C, Kong Y, Wang H, Wang S, Yu H, Liu X, Yang L, Jiang X, Li L, Li L: Homing of bone marrow mesenchymal stem cells mediated by sphingosine 1-phosphate contributes to liver fibrosis. J Hepatol 2009;50:1174-1183.
44. Meriane M, Duhamel S, Lejeune L, Galipeau J, Annabi B: Cooperation of matrix metalloproteinases with the RhoA/Rho kinase and mitogen-activated protein kinase kinase-1/extracellular signal-regulated kinase signaling pathways is required for the sphingosine-1-phosphate-induced mobilization of marrow-derived stromal cells. Stem Cells 2006;24:2557-2565.
45. Li M, Yu J, Li Y, Li D, Yan D, Qu Z, Ruan Q: CXCR4 positive bone mesenchymal stem cells migrate to human endothelial cell stimulated by ox-LDL via SDF-1alpha/CXCR4 signaling axis. Exp Mol Pathol 2010;88:250-255.
46. Yu J, Li Y, Li M, Qu Z, Ruan Q: Oxidized low density lipoprotein-induced transdifferentiation of bone marrow-derived smooth muscle-like cells into foam-like cells in vitro. Int J Exp Pathol 2010;91:24-33.
47. Parhami F, Jackson SM, Tintut Y, Le V, Balucan JP, Territo M, Demer LL: Atherogenic diet and minimally oxidized low density lipoprotein inhibit osteogenic and promote adipogenic differentiation of marrow stromal cells. J Bone Miner Res 1999;14:2067-2078.